Will You Give On #GivingTuesday?

November 26, 2018 3:48 am

The Clearity Foundation has joined #GivingTuesday, a global day of giving that harnesses the collective power of individuals, communities and organizations to encourage philanthropy and to celebrate generosity worldwide.

Celebrated on the Tuesday following Thanksgiving, and the widely recognized shopping … Read more

Clearity’s Teal Woman 10th Anniversary Celebration

October 10, 2018 4:21 pm

The Clearity Foundation held its Teal Woman 10th Anniversary Celebration on September 16, 2018, at the Paradise Point Resort. The event, themed, “Teal Woman: Celebrating Life. Honoring Courage. Recognizing Progress. Changing the Story for Ovarian Cancer,” helped us to shine … Read more

Clinical Trials Offer Promising New Treatments for Ovarian Cancer

February 5, 2018 9:10 pm

By: Deborah Zajchowski, PhD – Scientific Director, The Clearity Foundation

In the past three years, new hope has come to many women with ovarian cancer because of four new drugs that were approved for the treatment of this disease. These … Read more

Ovarian Cancer Clinical Trial Results: Data Points to Treatment Options Beyond Standard Chemotherapy

February 1, 2017 5:19 pm

By: Cory Bentley, PhD

Many women diagnosed with ovarian cancer could probably write a dissertation for an advanced degree on ovarian cancer. Whether women are newly diagnosed or have recurrent ovarian cancer, the new learning needed to make informed decisions

Read more

Clearity’s Precision Medicine Symposium Demonstrates Sea Change in Personalized Ovarian Cancer Treatment

May 2, 2016 8:38 pm

By: Cory Bentley, PhD

The Society for Gynecological Oncology (SGO) Meeting this March in San Diego brought together physicians and scientists from all over the world to share the latest research, treatments, and thinking in gynecological cancers including ovarian. Clearity … Read more

Molecular Profiling As a Necessity for Uncommon Ovarian Cancers

November 5, 2015 11:00 am

By: Laura Shawver

In 1998, Herceptin was approved for women with breast cancer whose tumors have extra copies of the Her2/ERBB2 gene and since that time, there have been more than 25 drugs approved to treat cancers with specific genetic … Read more

Novel Clinical Trial Designs Match Drugs to Patient’s Tumor Profiles

September 1, 2014 8:07 pm

By: Cory Bentley, PhD

Bringing new treatments to ovarian cancer patients is very challenging.  There are not as many patients diagnosed with this cancer as there are with other cancer types, such as breast, lung and colorectal, so there are … Read more

Eligibility Criteria in Clinical Trials: PARP Inhibitors

July 1, 2013 7:59 pm

By: Cory Bentley, PhD

Clearity first reported on drugs inhibiting PARP (Poly-ADP ribose polymerase), an important enzyme for tumor cell proliferation and survival, in its September 2010 patient newsletter.  At that time, PARP inhibitors were just entering clinical trials and

Read more

CA125 Becomes a Target for Destruction of Ovarian Cancer by Phase I Drug

May 1, 2013 7:50 pm

By: Cory Bentley, PhD

Most ovarian cancer patients have become familiar with CA125 blood level monitoring, but trial drug DMUC5754A from Genentech puts a new twist on this familiar blood marker of advanced ovarian cancer. CA125 (cancer antigen 125) also … Read more

Clinical Trials for Ovarian Cancer Patients: Why Now?

February 1, 2013 7:44 pm

By: Cory Bentley, PhD & Teresa Gallagher, PhD

Ovarian cancer is a very diverse disease on the molecular level. Different tumors have different key molecular players and potentially different Achilles’ heels. Researchers are making real progress in pinpointing key players … Read more